Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.

Article Details

Citation

Copy to clipboard

Kazanjian P, Armstrong W, Hossler PA, Lee CH, Huang L, Beard CB, Carter J, Crane L, Duchin J, Burman W, Richardson J, Meshnick SR

Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.

J Infect Dis. 2001 Mar 1;183(5):819-22. Epub 2001 Feb 1.

PubMed ID

11181161 [ View in PubMed

]

Abstract

This retrospective cohort study was conducted to determine whether Pneumocystis carinii cytochrome b gene mutations in patients with AIDS and P. carinii pneumonia (PCP) are associated with atovaquone exposure. Portions of the P. carinii cytochrome b genes that were obtained from 60 patients with AIDS and PCP from 6 medical centers between 1995 and 1999 were amplified and sequenced by using polymerase chain reaction. Fifteen patients with previous atovaquone prophylaxis or treatment exposure were matched with 45 patients with no atovaquone exposure. Cytochrome b coenzyme Q binding site mutations were observed in 33% of isolates from patients exposed to atovaquone, compared with 6% from those who were not (P=.018). There was no difference in survival 1 month after treatment between patients with or without cytochrome b mutations (P=.14). Thus, cytochrome b mutations are significantly more common in patients with AIDS and PCP with atovaquone exposure, but the clinical significance of these mutations remains unknown.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Atovaquone	Cytochrome b	Protein	Plasmodium falciparum	Yes	Inhibitor	Details